Literature DB >> 24012533

Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma.

Dong Chen1, Maximilian Gassenmaier2, Matthias Maruschke3, Rainer Riesenberg2, Heike Pohla2, Christian G Stief4, Wolfgang Zimmermann2, Alexander Buchner5.   

Abstract

PURPOSE: Epithelial-mesenchymal transition enhances tumor cell motility and has a critical role in invasion and metastasis in a number of carcinomas. A set of transcription factors acts as a master regulator of the epithelial-mesenchymal transition process. To our knowledge it is unknown whether epithelial-mesenchymal transition is important for clear cell renal cell carcinoma progression. Therefore, we comprehensively assessed mRNA levels of epithelial-mesenchymal transition associated genes in renal cell carcinoma as well as their prognostic relevance.
MATERIALS AND METHODS: We determined the expression of a set of 46 epithelial-mesenchymal transition related genes by oligonucleotide microarray and gene set enrichment analyses using RNA from 14 samples each of normal kidneys, and G1 and G3 primary renal cell carcinomas. Expression of select epithelial-mesenchymal transition genes was validated by real-time polymerase chain reaction in normal kidneys, primary renal cell carcinomas and metastases in an independent cohort of 112 patients. Results were combined with followup data for survival analysis.
RESULTS: The epithelial-mesenchymal transition gene set was preferentially expressed in primary renal cell carcinoma compared to normal tissue (false discovery rate 0.01). No difference was found between G1 and G3 tumors. Quantitative reverse transcriptase-polymerase chain reaction revealed down-regulation of critical epithelial-mesenchymal transition genes such as CDH2 and ZEB1 in metastases, suggesting epithelial-mesenchymal transition reversal during metastasis. Kaplan-Meier analysis demonstrated a better outcome in patients with low CXCR4, vimentin, fibronectin and TWIST1 mRNA levels. Multivariate analyses revealed that CXCR4 and VIM up-regulation represents an independent prognostic marker for poor cancer specific survival in patients with renal cell carcinoma.
CONCLUSIONS: Taken together, our data provide strong evidence that epithelial-mesenchymal transition occurs in renal cell carcinoma. Thus, interference with epithelial-mesenchymal transition in renal cell carcinoma might represent a future therapeutic option.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  CXC chemokine receptor; CXCR; EMT; ES; FDR; FN1; GSEA; MET; PCR; RCC; TGF-β; VIM; ZEB1; carcinoma; clear cell; enrichment score; epithelial-mesenchymal transition; false discovery rate; fc; fibronectin; fold change; gene expression; gene set enrichment analysis; kidney; mesenchymal-epithelial transition; polymerase chain reaction; prognosis; renal cell carcinoma; transforming growth factor-β; vimentin; zinc finger E-box binding homeobox 1

Mesh:

Substances:

Year:  2013        PMID: 24012533     DOI: 10.1016/j.juro.2013.08.052

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

Review 1.  Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Authors:  Francesco Piva; Matteo Giulietti; Matteo Santoni; Giulia Occhipinti; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Giovanni Principato; Rodolfo Montironi
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

2.  Up-regulation of E-cadherin by saRNA inhibits the migration and invasion of renal carcinoma cells.

Authors:  Jun Dai; Hongchao He; Dengqiang Lin; Chenghe Wang; Yu Zhu; Danfeng Xu
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

Review 3.  CXCR4 over-expression and survival in cancer: a system review and meta-analysis.

Authors:  Hongli Zhao; Liyuan Guo; Hong Zhao; Jiaxin Zhao; Hao Weng; Bin Zhao
Journal:  Oncotarget       Date:  2015-03-10

4.  Identification of recurrent regulated alternative splicing events across human solid tumors.

Authors:  Miri Danan-Gotthold; Regina Golan-Gerstl; Eli Eisenberg; Keren Meir; Rotem Karni; Erez Y Levanon
Journal:  Nucleic Acids Res       Date:  2015-04-23       Impact factor: 16.971

5.  Impact of an altered PROX1 expression on clinicopathology, prognosis and progression in renal cell carcinoma.

Authors:  Tao Lv; Yanfeng Liu; Jianping Zhang; Le Xu; Yu Zhu; Hankun Yin; Huimin An; Zongming Lin; Youhua Xie; Lian Chen
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

6.  DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.

Authors:  Nathaniel Weygant; Dongfeng Qu; Randal May; Ryan M Tierney; William L Berry; Lichao Zhao; Shweta Agarwal; Parthasarathy Chandrakesan; Harisha R Chinthalapally; Nicholas T Murphy; James D Li; Sripathi M Sureban; Michael J Schlosser; James J Tomasek; Courtney W Houchen
Journal:  Oncotarget       Date:  2015-02-10

Review 7.  Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.

Authors:  Pauline Hascoet; Franck Chesnel; Cathy Le Goff; Xavier Le Goff; Yannick Arlot-Bonnemains
Journal:  Front Oncol       Date:  2015-10-27       Impact factor: 6.244

8.  Snail heterogeneity in clear cell renal cell carcinoma.

Authors:  Laura Zaldumbide; Asier Erramuzpe; Rosa Guarch; Rafael Pulido; Jesús M Cortés; José I López
Journal:  BMC Cancer       Date:  2016-03-08       Impact factor: 4.430

9.  Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

Authors:  Maria Serova; Annemilaï Tijeras-Raballand; Celia Dos Santos; Matthieu Martinet; Cindy Neuzillet; Alfred Lopez; Dianne C Mitchell; Brad A Bryan; Guillaume Gapihan; Anne Janin; Guilhem Bousquet; Maria Eugenia Riveiro; Ivan Bieche; Sandrine Faivre; Eric Raymond; Armand de Gramont
Journal:  Oncotarget       Date:  2016-06-21

10.  Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma.

Authors:  Hana Mlcochova; Tana Machackova; Anja Rabien; Lenka Radova; Pavel Fabian; Robert Iliev; Katerina Slaba; Alexandr Poprach; Ergin Kilic; Michal Stanik; Martina Redova-Lojova; Marek Svoboda; Jan Dolezel; Rostislav Vyzula; Klaus Jung; Ondrej Slaby
Journal:  Sci Rep       Date:  2016-08-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.